3.05
0.54 (21.51%)
| Previous Close | 2.51 |
| Open | 2.48 |
| Volume | 1,530,151 |
| Avg. Volume (3M) | 1,252,766 |
| Market Cap | 117,309,352 |
| Price / Sales | 255.50 |
| Price / Book | 16.73 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -0.830 |
| Total Debt/Equity (MRQ) | 10.50% |
| Current Ratio (MRQ) | 2.22 |
| Operating Cash Flow (TTM) | -19.11 M |
| Levered Free Cash Flow (TTM) | -10.84 M |
| Return on Assets (TTM) | -97.10% |
| Return on Equity (TTM) | -290.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Gain Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
|
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.78% |
| % Held by Institutions | 8.14% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Potomac Capital Management, Inc. | 31 Dec 2025 | 1,010,000 |
| Jones Financial Companies Lllp | 31 Dec 2025 | 702,213 |
| Cambridge Investment Research Advisors, Inc. | 31 Dec 2025 | 568,645 |
| Dme Capital Management, Lp | 31 Dec 2025 | 566,130 |
| Cresset Asset Management, Llc | 31 Dec 2025 | 160,000 |
| Lpl Financial Llc | 31 Dec 2025 | 106,550 |
| 52 Weeks Range | ||
| Median | 8.00 (162.30%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 Dec 2025 | 8.00 (162.30%) | Buy | 2.88 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Jan 2026 | Announcement | Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week |
| 06 Jan 2026 | Announcement | Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 |
| 18 Dec 2025 | Announcement | Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease |
| 18 Dec 2025 | Announcement | Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |